

Investigator Gazetteer Report – Terminated Trials - Feb 2021

Terminated Trials

By Johan PE Karlberg, MD, PhD

<https://www.clinicaltrialmagnifier.org/>

Objective and Material

The objective of this report is to display the number and type of terminated industry-sponsored clinical trials.

The data represent industry-sponsored clinical trials for a four year period, i.e. for trials registered with the US trial registry (clinicaltrials.gov) between January 1, 2017 to December 31, 2020.

Results

The results are shown in Table 1, Table 2 and Table 3.

Trials that have been suspended, terminated or withdrawn have been grouped into one group labelled 'Terminated' – see Table 1.

Total number of Terminated Trials

Overall 1,243 studies were Terminated representing 6.38% of the total number of studies (Table 1). Phase II trials have a relatively larger number of Terminated studies (8.75%).

Table 1. Terminated trials: Number of industry-sponsored clinical trials by study status and study phase over a period of four full consecutive years (2017.01-2020.12).

Status	Phase I (n)	Phase II (n)	Phase III (n)	Phase IV (n)	NA (n)	Total
1. Planning	629	453	294	84	473	1,933
2. Recruiting	2,409	1,582	1,332	237	1,375	6,935
3. Ongoing	510	520	528	61	421	2,040
4. Completed	2,775	1,052	863	275	1,747	6,712
5. Suspended	35	30	14	2	40	121
7. Terminated	227	213	106	28	136	710
8. Withdrawn	96	111	69	31	105	412
9. Unknown	202	84	60	40	246	632
Total	6,883	4,045	3,266	758	4,543	19,495
Total 5+6+7 (n)	358	354	189	61	281	1,243
Total 5+6+7 (%)	5.20	8.75	5.79	8.05	6.19	6.38

Terminated Trials by Therapeutic Area

Table 2 provides the distribution of Terminated phase II/III trials over the most common therapeutic areas.

There is a variation in the proportion of trials Terminated in respect to therapeutic area; Psychiatric has the highest number of Terminated trials (12.9%) as compared with the lowest (2.8%) for Ophthalmology. Other areas with high termination rate are Pulmonary, Allergy, Gastroenterology and Neurology.

Table 2 also provides information about the thousands of study sites that were hurt by trial Termination. The number of sites terminated are highly therapeutic area dependent.

Investigator Gazetteer Report – Terminated Trials - Feb 2021

Table 2. Terminated phase II/III trials: Number of industry-sponsored phase II/III clinical trials by therapeutic area over a period of four full consecutive years (2017.01-2020.12).

Area	Trials (n)	Deleted (n)	Deleted (%)	Sites (n)
Oncology	1,734	115	6.63	2,019
Infectious	1,039	75	7.22	1,431
Neurology	581	54	9.29	1,254
Endocrinology	467	25	5.35	1,782
Dermatology	425	23	5.41	416
Cardiology	420	37	8.81	1,097
Gastroenterology	397	37	9.32	3,825
Ophthalmology	319	9	2.82	228
Allergy	296	30	10.14	832
Psychiatrics	272	35	12.87	763
Rheumatology	259	16	6.18	521
Hematology	247	15	6.07	152
Pulmonary	172	18	10.47	350
Urology	168	9	5.36	231
Orthopedics	110	8	7.27	66
Anesthesiology	105	9	8.57	228
Obstetrics / Gynecology	103	9	8.74	211

Terminated Trials by Disease

Table 3 provides information about the study termination rate among the most commonly studied diseases i.e. with at least 30 phase II/III trials over the four years of study.

The termination rate varies between 0% to 23.3% among the 66 diseases listed in Table 3 (next page).

Investigator Gazetteer Report – Terminated Trials - Feb 2021

Table 3. Terminated phase II/III trials: Number of industry-sponsored phase II/III clinical trials among the most common diseases studied over a period of four full consecutive years (2017.01-2020.12).

Area	Trials (n)	Deleted (n)	Deleted (%)	Sites (n)
GI BILIARY DISEASE	30	7	23.33	238
NEUR MUSCULAR DYSTROPHY	35	7	20.00	93
NEUR ALS	32	6	18.75	74
PSYCH DEPRESSION	81	14	17.28	341
INFECT RESP: SYNCYTIAL	30	5	16.67	78
ALLERGY ALLERGY	95	15	15.79	222
CARDIO HYPERTENSION PULM	38	6	15.79	192
ONC HEM: LEUKEMIA	96	14	14.58	215
NEUR PARKINSON	66	9	13.64	147
GI LIVER FATTY	68	9	13.24	693
CARDIO CARDIOMYOP/FAILURE	71	9	12.68	685
RESP COPD	53	6	11.32	188
NEUR EPILEPSY/SEIZURE	45	5	11.11	31
CARDIO THROMB/COAG	38	4	10.53	32
ONC ENT: NPC	68	7	10.29	11
ONC GI: COLORECTAL	59	6	10.17	23
ALLERGY ECZEMA/DERMATITIS	134	13	9.70	474
ONC HEM: MYELOMA	54	5	9.26	95
INFECT RESP: INFLUENZA/FLU	102	9	8.82	924
RHEUM LUPUS ERYTHEM.	34	3	8.82	75
HEM ANEMIA	57	5	8.77	45
PSYCH SCHIZOPHRENIA	49	4	8.16	146
INFECT GI: HEPATITIS B	51	4	7.84	11
ORTH MUSCULAR DISEASE	39	3	7.69	29
ONC DERM: MELANOMA	53	4	7.55	8
ONC BREAST	189	14	7.41	577
GI CROHN	54	4	7.41	316
INFECT HIV/AIDS	54	4	7.41	8
ONC HEM: LYMPHOMA	137	10	7.30	151
ONC SOLID TUMOR/CANCER	114	8	7.02	38
DERM PSORIASIS	115	8	6.96	102
ONC RESP: LUNG	296	20	6.76	542
INFECT GI: HEPATITIS C	31	2	6.45	21
ENDO DIABETES	234	15	6.41	1,688
NEUR MULTIPLE SCLEROSIS	64	4	6.25	33
NEUR MIGRAINE/H-ACHE	69	4	5.80	112
GI ULCERATIVE COLITIS	70	4	5.71	246
ANEST PAIN ACUTE	36	2	5.56	3
CARDIO HYPERTENSION	36	2	5.56	2
UROLOGY KIDNEY NEPHRITIS	36	2	5.56	24
NEUR NEUROPATHY	38	2	5.26	36
ONC CNS: GLIOMA	38	2	5.26	6
ONC GI: PANCREAS	38	2	5.26	7
NEUR ALZHEIMER/DEMENT	99	5	5.05	351
RHEUM ARTHRITIS/GOUT	201	10	4.98	443
ONC UROLOGY: BLADDER	62	3	4.84	116
DERM ACNE	43	2	4.65	2
HEM HAEMOPHILIA A/B	43	2	4.65	31
ONC OG: OVARY	70	3	4.29	71
RESP CYSTIC FIBROSIS	47	2	4.26	37
ONC GI: ESOPHAGEAL/GASTRIC	71	3	4.23	112
ONC UROLOGY: PROSTATE	71	3	4.23	11
UROLOGY KIDNEY FAILURE	50	2	4.00	17
INFECT RESP: COVID-19	290	11	3.79	56
CARDIO CHOLESTEROL/LIPIDS	86	3	3.49	65
ONC UROLOGY: KIDNEY	33	1	3.03	1
OPHTHAL MACULAR DEGENERATION	68	2	2.94	50
ONC OG: CERVIX	36	1	2.78	1
OPHTHAL GLAUCOMA	37	1	2.70	1
OPHTHAL DIABETIC	38	1	2.63	64
HEALTHY/PHARM	43	1	2.33	1
ONC GI: LIVER	60	1	1.67	4
OPHTHAL DRY EYE	63	0	0.00	0
DERM WRINKLES	35	0	0.00	0
INFECT RESP: PNEUMOCOCCAL	35	0	0.00	0
HEM HEMOGLOBINURIA	30	0	0.00	0